Literature DB >> 23536644

When less is more: a case of phenytoin toxicity.

Kit Robertson1, Conrad Brice von Stempel, Ian Arnold.   

Abstract

The authors present a case of an 87-year-old gentleman who presented with general deterioration, increased confusion, recurrent falls and unsteadiness. He was treated for a urinary tract infection but was found to deteriorate rapidly, developing bilateral nystagmus, marked pastpointing, dysarthria and central ataxia. He had a complex medical history including epilepsy controlled with long-term phenytoin. Phenytoin is 90% protein bound and displaced by bilirubin. At the time of deterioration his total phenytoin concentration was within the limits of the laboratory's recommended therapeutic range. The biochemistry report also denoted the patient was hypoalbuminaemic and hyperbilirubinaemic. His symptoms completely resolved with phenytoin dose reduction. The combination of low albumin and high bilirubin may cause an increase in the free phenytoin concentration, resulting in toxicity, despite the measured total phenytoin concentration being within the therapeutic interval.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23536644      PMCID: PMC3618739          DOI: 10.1136/bcr-2012-008023

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

1.  Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin.

Authors:  A Dasgupta; M J Crossey
Journal:  Am J Med Sci       Date:  1997-02       Impact factor: 2.378

2.  Plasma protein binding of azapropazone in patients with kidney and liver disease.

Authors:  E Jähnchen; K J Blanck; K H Breuing; H J Gilfrich; T Meinertz; D Trenk
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

3.  Phenytoin toxicity associated with hypoalbuminemia in critically ill patients.

Authors:  J Lindow; E F Wijdicks
Journal:  Chest       Date:  1994-02       Impact factor: 9.410

Review 4.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

5.  Plasma protein binding of frusemide in liver disease: effect of hypoalbuminaemia and hyperbilirubinaemia.

Authors:  A Viani; M Carrai; G M Pacifici
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

6.  Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients.

Authors:  Ji-Man Hong; Young-Chul Choi; Won-Joo Kim
Journal:  Yonsei Med J       Date:  2009-08-19       Impact factor: 2.759

  6 in total
  4 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

2.  Phenytoin Toxicity Treatment with Haemodialysis in Epilepsy due to Glioblastoma Multiforme: Case Report and Review of the Literature.

Authors:  Karishma Sharma; Aditi Vakil; Ahmed Sokwala; Dilraj Sokhi
Journal:  Case Rep Neurol       Date:  2019-12-10

3.  The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of SCN8A encephalopathy.

Authors:  Erin M Baker; Christopher H Thompson; Nicole A Hawkins; Jacy L Wagnon; Eric R Wengert; Manoj K Patel; Alfred L George; Miriam H Meisler; Jennifer A Kearney
Journal:  Epilepsia       Date:  2018-05-21       Impact factor: 5.864

Review 4.  Acquired ataxias: the clinical spectrum, diagnosis and management.

Authors:  Wolfgang Nachbauer; Andreas Eigentler; Sylvia Boesch
Journal:  J Neurol       Date:  2015-03-26       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.